A double‐blind, randomized, placebo‐controlled, parallel group study of <scp>THC</scp>/<scp>CBD</scp> spray in peripheral neuropathic pain treatment

These findings demonstrate that, in a meaningful proportion of otherwise treatment-resistant patients, clinically important improvements in pain, sleep quality and SGIC of the severity of their condition are obtained with THC/CBD spray. THC/CBD spray was well tolerated and no new safety concerns were identified.